Gennex Laboratories Ltd Share Price Today - Gennex Laboratories Ltd Stock Price Live NSE/BSE

Gennex Laboratories Ltd

NSE: BSE: 531739

₹9.40

(0.86%)

Mon, 23 Mar 2026, 07:57 pm

MTF 5xInvest in Gennex Laboratories Ltd with 5x Leverage Buy with MTF

Market Cap2.14B

PE Ratio12.68

Dividend0

Health Technology

Pharmaceuticals: Major

24.5K

Gennex Laboratories Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
228.37
Net Profit
18.12
P/B
1.51
Sector P/E
31.86
P/E
15.06
EV/EBITDA
8.47
Debt/Equity (Industry)
0.16
Interest Cover (Industry)
20.07
ROCE (Industry)
20.49
RONW (Industry)
17.59
ROE
10.15
ROCE
12.40
Debt/Equity
0.04
EPS (TTM)
0.72
Dividend Yield
0
Book Value
8.79
Interest Cover
6.93

Analysis

all

Pros

Gennex Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Gennex Laboratories is profitable, therefore cash runway is not a concern.
Gennex Laboratories is profitable, therefore cash runway is not a concern.
Debt is well covered by operating cash flow (41.8%, greater than 20% of total debt).
Debt is covered by short term assets, assets are 7.2x debt.

Cons

Unable to evaluate Gennex Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Gennex Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.
High level of physical assets or inventory.
Gennex Laboratories is not covered by any analysts.
Gennex Laboratories has significant price volatility in the past 3 months.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	23.62	23.62	19.83	18.42	18.42
FII	0	0	0	0	0
DII	0.00	0.00	0.00	0.00	0.00
Public	76.38	76.38	80.17	81.58	81.58
Government	0	0	0	0	0

Technical Analysis

RSI

20.45

MACD

-0.79

50 DMA

11.66

200 DMA

12.79

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	15.87	13.79	12.52	11.71	10.44	9.63	7.55
Fibonacci	13.79	13.00	12.51	11.71	10.92	10.43	9.63
Camarilla	11.81	11.62	11.43	11.71	11.05	10.86	10.67

Pivots Level: Classic

+4.16

15.87

+2.08

13.79

+0.80

12.52

11.71

Pivot Point

LTP: 8.47

-1.28

10.44

-2.08

9.63

-4.16

7.55

Moving Average

SMAEMA

Period

Value

10-EMA
9.54
20-EMA
10.17
30-EMA
10.64
50-EMA
11.31
100-EMA
12.12
200-EMA
12.86

Announcement Date	Purpose	Action	Ex Date
14 Feb 2026	board-meetings	Quarterly Results
14 Nov 2025	board-meetings	Quarterly Results, Half Yearly Results
04 Sept 2025	agm
06 Sept 2024	agm
04 Dec 2023	egm
09 Sept 2023	agm
06 Sept 2022	agm
18 Jul 2022	rights	1:2 Rights Issue of Equity Shares	22 Jul 2022
22 Jun 2022	rights	Right Issue of Equity Shares	22 Jul 2022
06 Sept 2021	agm

Gennex Laboratories Ltd

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd

Divis Laboratories Ltd

Lupin Ltd

Gennex Laboratories Ltd About

Gennex Laboratories is engaged in the business of manufacturing of Bulk Drugs and Intermediaries.

Industry

Pharmaceuticals - Indian - Bulk Drugs

Founded

1990

Headquarters

CEO

Arihant Baid

Employees

Contact

Website

http://www.gennexlab.com

investorrelations@gennexlab.com

Phone

91-8458-279406/279516

Location

Survey No 133 Bollaram, Jinnaram Mandal, Medak, Telangana, 502325

Year	History
1994	The company was converted to a Public Limited Company by a resolution passed by its members at the Extraordinary General Body Meeting held on 3rd November. Mr. Vinod Baid and his associates acquired the entire holding of Pharmasia Limited in November.
1995	A fresh certificate of incorporation consequent upon the change of name of the company was issued by the Registrar of Companies, Andhra Pradesh, on 22nd February. A fresh certificate of incorporation consequent upon the conversion of the company was issued by the Registrar of Companies, Andhra Pradesh, on 15th February. The trial production was completed in September.
2007	The company name was changed from Prudential Pharmaceuticals Ltd to Gennex Laboratories Ltd.
2009	The company split its face value of shares from Rs 10 to Re 1.
2022	The company issued rights shares of Rs. 1 in the ratio of 1:2 at a premium of Rs. 5 per share.

Client Name	Order Side	QTY	Avg Price	Date
KAMAL KUMAR DUGAR AND CO ( PROP : KAMAL KUMAR DUGAR)	Sell	1175000	13.81	15 Oct 2025
DORITE TRACON PRIVATE LIMITED	Buy	1501719	13.75	15 Oct 2025
NARANTAK DEALCOMM LIMITED	Buy	2000000	13.37	14 Oct 2025
TROPICAL AGRO SYSTEM INDIA PRIVATE LIMITED	Sell	1700000	11.01	30 Sept 2025
MARYADA B	Buy	1207467	12.73	12 Mar 2025
KAMAL KUMAR DUGAR AND CO ( PROP : KAMAL KUMAR DUGAR)	Sell	1174666	22.62	18 Oct 2024
L7 HITECH PRIVATE LIMITED	Sell	2452005	22.87	10 Oct 2024
MANOJ KUMAR DUGAR (HUF)	Sell	2500000	20.66	07 Oct 2024
HEMANT KUMAR JAIN	Sell	4000000	20.64	07 Oct 2024
MANSI SHARE & STOCK ADVISORS PRIVATE LIMITED	Buy	2420000	22.57	07 Oct 2024

Gennex Laboratories Ltd News

Gennex Labs Q3 FY26 Results Published in Newspapers

Gennex Laboratories Limited published its Q3 FY26 unaudited financial results in newspapers as per regulatory requirements, with results approved by the Board on February 14, 2026.

17 Feb 2026

co actions results

Gennex Labs Independent Director Resigns

Ms. Shilpa Bung resigned as Non-Executive Independent Women Director of Gennex Laboratories with immediate effect on February 14, 2026, citing new role as CS Hyderabad Chapter Chairperson.

14 Feb 2026

stocks

Gennex Labs Q3FY26 Net Profit Rises 18.3% YoY

Gennex Laboratories reported consolidated net profit of ₹599.22 lakhs for Q3FY26, up 18.3% YoY. Revenue from operations grew 7.1% to ₹4,036.64 lakhs with strong performance in bulk drugs.

14 Feb 2026

co actions results

Gennex Laboratories Reports Strong Growth in Quarterly Results with Revenue Rising to Rs. 2,928 Lakhs

Gennex Laboratories Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2025, showing consolidated revenue of Rs. 2,928.04 lakhs compared to Rs. 2,468.59 lakhs in the previous year quarter. The pharmaceutical company, which operates in bulk drugs manufacturing including Guaifenesin and Methocarbamol with international operations, reported consolidated net profit of Rs. 551.15 lakhs for the quarter with earnings per share of Rs. 0.207.

14 Nov 2025

earnings

Gennex Laboratories Reports Strong Q1 Growth with 20% Revenue Jump and 176% Profit Surge

Gennex Laboratories reported standalone revenue of Rs 2,564 lacs for the quarter ended June 30, 2025, up from Rs 2,133.40 lacs in the same quarter last year. Net profit increased significantly to Rs 414.95 lacs compared to Rs 416.60 lacs in the previous year quarter. On a consolidated basis, revenue reached Rs 3,417.75 lacs versus Rs 2,832.18 lacs in the prior year quarter, while net profit was Rs 501.64 lacs compared to Rs 465.84 lacs. The company's paid-up equity share capital increased to Rs 2,314.48 lacs from Rs 2,274.48 lacs. Basic earnings per share stood at Rs 0.179 for standalone and Rs 0.217 for consolidated results. The board meeting was held on August 14, 2025, where directors approved the unaudited financial statements along with limited review reports from statutory auditors.

14 Aug 2025

earnings

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800